ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO868

Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan with Irbesartan for IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Wadhwani, Shikha, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Bensink, Mark Eliot, Travere Therapeutics Inc, San Diego, California, United States
  • Peipert, John D., Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Ayoub, Isabelle, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
  • Preciado, Priscila, Travere Therapeutics Inc, San Diego, California, United States
  • Garbinsky, Diana, RTI Health Solutions Research Triangle Park, Research Triangle Park, North Carolina, United States
  • Bennett, Lee, RTI Health Solutions Research Triangle Park, Research Triangle Park, North Carolina, United States
  • Gong, Wu, Travere Therapeutics Inc, San Diego, California, United States
  • Inrig, Jula K., Travere Therapeutics Inc, San Diego, California, United States
  • Komers, Radko, Travere Therapeutics Inc, San Diego, California, United States
Background

In the phase 3, double-blind PROTECT trial (NCT03762850), sparsentan (SPAR), a dual endothelin and angiotensin II receptor antagonist (DEARA), showed efficacy in reducing proteinuria and preserving renal function compared with a maximally tolerated dose of irbesartan (IRB) in patients with immunoglobulin A nephropathy (IgAN). Safety profiles for the two treatments were similar. This analysis aimed to evaluate the effect of SPAR compared with IRB on patient-reported outcomes (PROs) in patients with IgAN enrolled in PROTECT.

Methods

Adult patients were randomized to receive SPAR or IRB for 110 weeks. The Kidney Disease Quality of Life–36 (KDQOL-36) PRO measure was administered at baseline and at weeks 24, 48, 70, 94, and 110. Changes from baseline in Physical Component Summary, Mental Component Summary, Bodily Pain, and kidney-targeted subscale scores were analyzed using least-squares means from mixed models for repeated measures. A score change of 5 was considered clinically meaningful. Time-to-event endpoints, including first improvement, were analyzed using Cox models.

Results

Baseline KDQOL-36 scores were similar for patients randomized to SPAR and IRB. In general, least-squares mean changes from baseline indicated an improvement in Burden of Kidney Disease (BKD) score (week 110 difference [SPAR − IRB], 5.1; 95% confidence interval [CI], 0.45-9.67; P < 0.05]), while other scores were stable through week 110. Hazard ratios for time to first improvement in BKD score (1.51; 95% CI, 1.15-1.97) favored SPAR (Figure A).

Conclusion

For patients with IgAN, analysis of PROs from the PROTECT trial suggests that patients receiving SPAR have less burden of kidney disease over time and a general trend toward improved health-related quality of life compared with those receiving a maximally tolerated dose of IRB.

Funding

  • Commercial Support – Travere Therapeutics